HORSHAM, PA--(Marketwire - Jun 6, 2012) - Clinical Ink, the pioneering provider of eSource solutions for clinical trials, announced today that the company was named to the prestigious 2012 Cool Vendor List for life sciences. In particular, Gartner analyst Steve Lefebure cited the potential to eliminate errors, cut costs, reduce timelines, and simplify clinical trial processes as reasons to include Clinical Ink on the list this year.
"Recognition from an organization as objective, respected and knowledgeable as Gartner is an important validation of our business model," commented Ed Seguine, CEO of Clinical Ink. "The Clinical Ink approach to eSource shifts the focus of clinical trial data collection to the point of care -- during the subject visit. Doing so dramatically simplifies the entire clinical trial process and our early customers have seen remarkable early results: validated data available within 30 minutes, 70% of monitoring activity performed remotely, and sites that actually want to use technology because it improves their work, too."
Clinical Ink is the only company on the list to focus exclusively on clinical operations. As the Gartner report points out, Clinical Ink "has significant disruptive potential" and could transform the current business model. The potential to "eliminate steps and streamline the clinical study data capture process" has far-reaching implications for sites, sponsors, and CROs. Importantly, the FDA has signaled a willingness to encourage and promote change with the recent eSource and Risk-Based Monitoring draft guidance documents.
"We are honored to be included in the 'Cool Vendor' report," said Doug Pierce, Founder and President of Clinical Ink. "Clinical Ink has worked for several years to develop a comprehensive eSource solution to the problem of capturing and reviewing clinical trial data. We will continue to build capabilities that will allow customers to conduct clinical research more quickly, more confidently, and more affordably."
According to PhRMA, over the last five years the industry has spent nearly $250 Billion on clinical research; nearly $150 Billion on phase 1-3 clinical trials. Real productivity improvement and cost controls are urgently needed and the current technology solutions and organizational processes are incapable of bringing about the necessary change.
About Clinical Ink, Inc.
Clinical Ink has pioneered the development of eSource technology for use in clinical trials. SureSource® replaces paper source documents and CRFs with intuitive electronic forms that maintain the natural workflow, ease of use, and mobility of paper chart. Unlike EDC systems, our approach to eSource captures/validates data during the subject visit. As a result, data queries are dramatically reduced, SDV is eliminated, monitoring is performed real-time and remotely, and validated clinical data is available within minutes. Clinical Ink has offices in Philadelphia and Winston-Salem. For more information visit www.clinicalink.com or call 800-301-5033.
Disclaimer:
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Contact Information:
Contact:
Doug Pierce
Clinical Ink, Inc.
336-464-7401